384 related articles for article (PubMed ID: 28760226)
1. Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.
Morillas C
Med Clin (Barc); 2016 Nov; 147 Suppl 1():49-53. PubMed ID: 28760226
[TBL] [Abstract][Full Text] [Related]
2. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Handelsman Y
Endocr Pract; 2015 Sep; 21(9):1054-65. PubMed ID: 26132997
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
4. Clinical profile of patients with type 2 diabetes mellitus treated with sodium- glucose cotransporter-2 inhibitors and experience in real-world clinical practice in Spain.
Cuatrecasas G; Goñi-Goicoechea F
Med Clin (Barc); 2016 Nov; 147 Suppl 1():30-34. PubMed ID: 28760223
[TBL] [Abstract][Full Text] [Related]
5. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
[TBL] [Abstract][Full Text] [Related]
6. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
Shin JI
Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
[TBL] [Abstract][Full Text] [Related]
7. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
8. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.
Steen O; Goldenberg RM
Can J Diabetes; 2017 Oct; 41(5):517-523. PubMed ID: 28942789
[TBL] [Abstract][Full Text] [Related]
9. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
10. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitors in the treatment of type 2 diabetes.
Hasan FM; Alsahli M; Gerich JE
Diabetes Res Clin Pract; 2014 Jun; 104(3):297-322. PubMed ID: 24735709
[TBL] [Abstract][Full Text] [Related]
12. [Contributions of SGLT-2 and new drugs under investigation].
Mediavilla Bravo JJ
Semergen; 2014 Jul; 40 Suppl 2():34-40. PubMed ID: 25311718
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin for the treatment of type 2 diabetes.
Jahagirdar V; Barnett AH
Expert Opin Pharmacother; 2014 Nov; 15(16):2429-41. PubMed ID: 25301180
[TBL] [Abstract][Full Text] [Related]
15. [Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
Mauricio D
Med Clin (Barc); 2013 Sep; 141 Suppl 2():31-5. PubMed ID: 24444522
[TBL] [Abstract][Full Text] [Related]
16. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
Lee S
Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
[TBL] [Abstract][Full Text] [Related]
17. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Cardiol; 2017 Jul; 120(1S):S59-S67. PubMed ID: 28606346
[TBL] [Abstract][Full Text] [Related]
18. Approaching to DM2 through sodium-glucose cotransporter-2: does it make sense?
Segura J
Med Clin (Barc); 2016 Nov; 147 Suppl 1():22-25. PubMed ID: 28760221
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
Tang H; Dai Q; Shi W; Zhai S; Song Y; Han J
Diabetologia; 2017 Oct; 60(10):1862-1872. PubMed ID: 28725912
[TBL] [Abstract][Full Text] [Related]
20. Renal safety profile of sodium-glucose cotransporter-2 inhibitors and other safety data.
Gómez-Fernández P; Fernández-García D
Med Clin (Barc); 2016 Nov; 147 Suppl 1():44-48. PubMed ID: 28760225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
